Latest developments in the treatment of Hepatitis B

Minerva Gastroenterologica e Dietologica

Volumn 62, Issue 1, 2016, Pages 88-102

  Dandri, Maura ^a,b   Petersen, Joerg ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b German Center for Infection Research (DZIF)   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Hepatitis B; Immune system; Therapeutics

Indexed keywords

ANTIVIRUS AGENT; ALPHA INTERFERON; ENZYME INHIBITOR; HEPATITIS B SURFACE ANTIGEN; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS B; GENE EXPRESSION; GENE SILENCING; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; REVIEW; RNA INTERFERENCE; VIRUS ASSEMBLY; VIRUS ENTRY; VIRUS INHIBITION; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; HEPATITIS B; HEPATITIS B, CHRONIC; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 84961654726     PISSN: 1121421X     EISSN: 18271642     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res 2008;134:235-49.
2. Baumert TF, Meredith L, Ni Y, Felmlee DJ, McKeating JA, Urban S. Entry of hepatitis B and C viruses - recent progress and future impact. Curr Opin Virol 2014;4:58-65.
3. Glebe D, Urban S. Viral and cellular determinants involved in hepadnaviral entry. World J Gastroenterol 2007;13:22-38.
4. Urban S, Bartenschlager R, Kubitz R, Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 2014;147:48-64.
5. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. elife 2012;1:e00049.
6. Stieger B. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. Handb Exp Pharmacol 2011:205-59.
7. Macovei A, Radulescu C, Lazar C, Petrescu S, Durantel D, Dwek RA, Zitzmann N, et al. Hepatitis B virus requires intact caveolin-1 function for productive infection in HepaRG cells. J Virol 2010;84:243-53.
8. Urban S, Schulze A, Dandri M, Petersen J. The replication cycle of hepatitis B virus. J Hepatol 2011;52:282-4.
9. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009;51:581-92.
10. Koniger C, Wingert I, Marsmann M, Rosler C, Beck J, Nassal M. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci U S A 2014;111:E4244-4253.
11. Hoffmann J, Boehm C, Himmelsbach K, Donnerhak C, Roettger H, Weiss TS, Ploen D, et al. Identification of alpha-taxilin as an essential factor for the life cycle of hepatitis B virus. J Hepatol 2013;59:934-41.
12. Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut 2012;61(SUPPL. 1):i6-17.
13. Lang T, Lo C, Skinner N, Locarnini S, Visvanathan K, Mansell A. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol 2011;55:762-9.
14. Lucifora J, Arzberger S, Durantel D, Belloni L, Strubin M, Levrero M, Zoulim F, et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 2011;55:996-1003.
15. Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. J Virol 2004;78:12725-34.
16. Asabe S, Wieland SF, Chattopadhyay PK, Roederer M, Engle RE, Purcell RH, Chisari FV. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 2009;83:9652-62.
17. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65-91.
18. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284:825-9.
19. Wieland SF, Spangenberg HC, Thimme R, Purcell RH, Chisari FV. Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci U S A 2004;101:2129-34.
20. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012;61:1754-64.
21. Giersch K, Allweiss L, Volz T, Helbig M, Bierwolf J, Lohse AW, Pollok JM, et al. Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBv monoinfection. J Hepatol 2015;63:346-53.
22. Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, Brendish N, Lascar RM, et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009;137:1289-300.
23. Op den Brouw ML, Binda RS, van Roosmalen MH, Protzer U, Janssen HL. van der Molen RG, Woltman AM. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 2009;126:280-9.
24. Xu Y, Hu Y, Shi B, Zhang X, Wang J, Zhang Z, Shen F, et al. HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol 2009;46:2640-6.
25. Visvanathan K, Skinner NA, Thompson AJ, Riordan SM, Sozzi V, Edwards R, Rodgers S, et al. regulation of tolllike receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007;45:102-10.
26. Frelin L, Wahlstrom T, Tucker AE, Jones J, Hughes J, Lee Bo, Billaud JN, et al. A mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection. J Virol 2009;83:1379-92.
27. Volz T, Lutgehetmann M, Wachtler P, Jacob A, Quaas A, Murray JM, Dandri M, et al. impaired intrahepatic Hepatitis B Virus Productivity Contributes to Low Viremia in Most HBeAg-Negative Patients. Gastroenterology 2007;133:843-52.
28. Wei C, Ni C, Song T, Liu Y, Yang X, Zheng Z, Jia Y, et al. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol 2010;185:1158-68.
29. Volz T, Allweiss L, Ben MM, Warlich M, Lohse AW, Pollok JM, Alexandrov A, et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 2013;58:861-7.
30. Nguyen T, Locarnini S. Hepatitis: Monitoring drug therapy for hepatitis B-a global challenge? Nat Rev Gastroenterol Hepatol 2009;6:565-7.
31. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-8.
32. Sung JJ, Wong ML, Bowden S, Liew CT, Hui AY, Wong VW, Leung NW, et al. intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005;128:1890-7.
33. Wong DK, Yuen MF, Ngai VW, Fung J, Lai CL. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther 2006;11:909-16.
34. Lutgehetmann M, Volzt T, Quaas A, Zankel M, Fischer C, Dandri M, Petersen J. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther 2008;13:57-66.
35. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, et al. Peginterferon alpha-2b plus adefovir induce strong cccDna decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44:675-84.
36. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeag-negative chronic hepatitis B. Hepatology 2009;49:1141-50.
37. Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeag-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012;143:629-636 e621.
38. Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, Mutimer D, et al. entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in caucasians. Gut 2015;64:1289-95.
39. Allweiss L, Volz T, Lutgehetmann M, Giersch K, Bornscheuer T, Lohse AW, Petersen J, et al. Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration. J Hepatol 2014;60:500-7.
40. Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, Tillmann HL, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol 2011;55:1121-31.
41. Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, Mach T, et al. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-alpha2b: relation to response and HBV genotype. Antivir Ther 2012;17:9-17.
42. Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, Tabak F, Cakaloglu Y, Lanza AG, et al. validation of a stopping rule at week 12 using HBsag and HBv Dna for HBeAgnegative patients treated with peginterferon alfa-2a. J Hepatol 2012;56:1006-11.
43. Lampertico P, Liaw YF. New perspectives in the therapy of chronic hepatitis B. Gut 2012;61(SUPPL. 1):i18-24.
44. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, et al. Early serum HBsag drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-7.
45. Sonneveld MJ, Zoutendijk R, Hansen BE, Janssen HL. Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir. Antivir Ther 2012;17:1605-8.
46. Thimme R, Dandri M. Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? J Hepatol 2013;58:205-9.
47. Bettinger D, Knuppel E, Euringer W, Spangenberg HC, Rossle M, Thimme R, Schultheiss M. Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPSS) in 40 patients with hepatocellular carcinoma. Aliment Pharmacol Ther 2015;41:126-36.
48. Micco L, Peppa D, Loggi E, Schurich A, Jefferson L, Cursaro C, Panno AM, et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol 2013;58:225-33.
49. Das A, Hoare M, Davies N, Lopes AR, Dunn C, Kennedy PT, Alexander G, et al. Functional skewing of the global cD8 t cell population in chronic hepatitis B virus infection. J Exp Med 2008;205:2111-24.
50. Wieland SF, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari F V. Interferon prevents formation of replication competent hepatitis B virus rna-containing nucleocap-sids. Proc Natl Acad Sci U S A 2005;102:9913-7.
51. Xu C, Guo H, Pan XB, Mao R, Yu W, Xu X, Wei L, et al. Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol 2010;84:9332-40.
52. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 2012;122:529-37.
53. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014;343:1221-8.
54. Marcellin P, Buti M, Krastev Z, de Man RA, Zeuzem S, Lou L, Gaggar A, et al. Kinetics of hepatitis B surface antigen loss in patients with HBeag-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. J Hepatol 2014;61:1228-37.
55. Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F, Streinu-Cercel A, et al. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). Hepatology 2015;61:1512-22.
56. Xie Q, Zhou H, Bai X, Wu S, Chen JJ, Sheng J, Xie Y, et al. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B. Clin Infect Dis 2014;59:1714-23.
57. Marcellin P, Wursthorn K, Wedemeyer H, Chuang WL, Lau G, Avila C, Peng CY, et al. Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. J Hepatol 2015;62:41-7.
58. Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, et al. switching from entecavir to PegiFn alfa-2a in patients with HBeag-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol 2014;61:777-84.
59. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85.
60. Petersen J, Ratziu V, Buti M, Janssen HL, Brown A, Lampertico P, Schollmeyer J, et al. entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol 2012;56:520-6.
61. Petersen J, Unger S, Buti M, Wursthorn K, Lutgehtemann M, Lampertico P, Sarrazin C, et al. P1089 add-on therapy with entecavir plus tenofovir due to viral resistance or partial responses followed by monotherapy in chbpatients: final results from an international multicentre study. J Hepatol 2014;60:S440.
62. Galle PR, Hagelstein J, Kommerell B, Volkmann M, Schranz P, Zentgraf H. In vitro experimental infection of primary human hepatocytes with hepatitis B virus. Gastroenterology 1994;106:664-73.
63. Gripon P, Diot C, Guguen-Guillouzo C. Reproducible high level infection of cultured adult human hepatocytes by hepatitis B virus: effect of polyethylene glycol on adsorption and penetration. Virology 1993;192:534-40.
64. Gripon P, Diot C, Theze N, Fourel I, Loreal O, Brechot C, Guguen-Guillouzo C. Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. J Virol 1988;62:4136-43.
65. Schulze-Bergkamen H, Untergasser A, Dax A, Vogel H, Buchler P, Klar E, Lehnert T, et al. Primary human hepatocytes-a valuable tool for investigation of apoptosis and hepatitis B virus infection. J Hepatol 2003;38:736-44.
66. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t) ide analogues. Gastroenterology 2009;137:1593-1608 e1591-1592.
67. Durantel D, Carrouee-Durantel S, Werle-Lapostolle B, Brunelle MN, Pichoud C, Trepo C, et al. A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology 2004;40:855-64.
68. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006;131:1253-61.
69. Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouee-Durantel S, Villeneuve JP, Trepo C, et al. susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005;41:1391-8.
70. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 2002;99:15655-60.
71. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Falth M, Stindt J, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 2014;146:1070-83.
72. Engelke M, Mills K, Seitz S, Simon P, Gripon P, Schnolzer M, Urban S. Characterization of a hepatitis B and hepatitis delta virus receptor binding site. Hepatology 2006;43:750-60.
73. Hantz O, Parent R, Durantel D, Gripon P, Guguen-Guillouzo C, Zoulim F. Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells. J Gen Virol 2009;90:127-35.
74. Walter E, Keist R, Niederost B, Pult I, Blum HE. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. Hepatology 1996;24:1-5.
75. Petersen J, Dandri M, Mier W, Lutgehetmann M, Volz T, von Weizsacker F, Haberkorn U, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008;26:335-41.
76. Volz T, Allweiss L, MB MB, Warlich M, Lohse AW, Pollok JM, Alexandrov A, et al. The entry inhibitor Myrcludex-B effciently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 2013;58:861-7.
77. Lutgehetmann M, Mancke LV, Volz T, Helbig M, Allweiss L, Bornscheuer T, Pollok JM, et al. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology 2012;55:685-94.
78. Watashi K, Urban S, Li W, Wakita T. NTCP and beyond: opening the door to unveil hepatitis B virus entry. Int J Mol Sci 2014;15:2892-905.
79. Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K, Lohmann V, et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepa-tol 2014;60:723-31.
80. Phillips S, Chokshi S, Chatterji U, Riva A, Bobardt M, Williams R, Gallay P, et al. Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production. Gastroenterology 2015;148:403-414 e407.
81. Zhang TY, Yuan Q, Zhao JH, Zhang YL, Yuan LZ, Lan Y, Lo YC, et al. Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut 2015 [Epub ahead of print].
82. Wong DK, Yuen MF, Yuan H, Sum SS, Hui CK, Hall J, Lai CL. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 2004;40:727-37.
83. Laras A, Koskinas J, Dimou E, Kostamena A, Hadziyannis SJ. Intrahepatic levels and replicative activity of co-valently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 2006;44:694-702.
84. Lutgehetmann M, Volz T, Kopke A, Broja T, Tigges E, Lohse AW, Fuchs E, et al. In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. Hepatology 2010;52:16-24.
85. Seeger C, Sohn JA. Targeting hepatitis B virus with CRISPR/Cas9. Mol Ther Nucleic Acids 2014;3:e216.
86. Kennedy EM, Bassit LC, Mueller H, Kornepati AV, Bogerd HP, Nie T, Chatterjee P, et al. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided Dna endonuclease. Virology 2015;476:196-205.
87. Lin SR, Yang HC, Kuo YT, Liu CJ, Yang TY, Sung KC, Lin YY, et al. The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In vivo. Mol Ther Nucleic Acids 2014;3:e186.
88. Wooddell CI, Rozema DB, Hossbach M, John M, Hamilton HL, Chu Q, Hegge JO, et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther 2013;21:973-85.
89. Lanford RE, Guerra B, Chavez D, Giavedoni L, Hodara VL, Brasky KM, Fosdick A, et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 2013;144:1508-1517, 1517 e1501-1510.
90. Brezillon N, Brunelle MN, Massinet H, Giang E, Lamant C, Dasilva L, Berissi S, et al. Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice. PLoS One 2011;6:e25096.
91. Wang XY, Wei ZM, Wu GY, Wang JH, Zhang YJ, Li J, Zhang HH, et al. In vitro inhibition of HBv replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations. Antivir Ther 2012;17:793-803.
92. Xu YB, Yang L, Wang GF, Tong XK, Wang YJ, Yu Y, Jing JF, et al. Benzimidazole derivative, BM601, a novel inhibitor of hepatitis B virus and HBsAg secretion. Antiviral Res 2014;107:6-15.
93. Gane EJ, Lim YS, Gordon SC, Visvanathan K, Sicard E, Fedorak RN, Roberts S, et al. the oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol 2015;63:320-8.
94. Buti M, Fung S, Gane E, Afdhal NH, Flisiak R, Gurel S, Flaherty JF, et al. long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int 2015;9:243-50.
95. King TH, Kemmler CB, Guo Z, Mann D, Lu Y, Coeshott C, Gehring AJ, et al. A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance. PLoS One 2014;9:e101904.
96. Martin P, Dubois C, Jacquier E, Dion S, Mancini Bourgine M, Godon O, Kratzer R, et al. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut 2015;64:1961-71.
97. Obeng-Adjei N, Hutnick NA, Yan J, Chu JS, Myles DJ, Morrow MP, Sardesai N Y, et al. Dna vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques. Cancer Gene Ther 2013;20:652-62.
98. Koh S, Bertoletti A. Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response? Med Microbiol Immunol 2015;204:87-94.
99. Krebs K, Bottinger N, Huang LR, Chmielewski M, Arzberger S, Gasteiger G, Jager C, et al. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 2013;145:456-65.